From the Washington Post:
Drug Importation Foes Speak Out
Although the event was billed as the public's only chance to testify before a federal task force studying the increasingly common practice of drug importation, many of the speakers at yesterday's hearing turned out to have financial ties to the pharmaceutical industry, which has vehemently opposed efforts to legalize buying prescription drugs from Canada or elsewhere.

The day-long session featured criticism of drug importation by a former New York City police commissioner, a former administration attorney and a self-professed patient advocate who all had one thing in common: They receive money from drug makers. Pharmaceutical executives, a representative of the industry's lobbying arm, and consumer groups that receive some industry funding were also given speaking slots.

From the Advocate:
Federal drug reimportation hearing focuses on Norvir
A hearing Wednesday by the Department of Health and Human Services on the issue of reimporting cheaper medications to U.S. consumers from other Western countries focused on the anti-HIV drug Norvir, which late last year increased in price in the United States by 400%. AIDS groups and consumer advocates argued at the hearing that U.S. citizens should be allowed to purchase medications from foreign pharmacies, particularly those in Canada and other Western nations, where Norvir costs as little as $720 per year. The price hike by Abbott Laboratories on Norvir in the United States raised the drug's cost from about $1,500 per year to nearly $7,800.